Congress updates
Start a conversation with your colleagues on clinical recommendations from 2021 and 2020 osteoarthritis (OA) congresses.
- Watch short videos from EULAR 2021 of OA experts in a roundtable discussion
- Catch up on key takeaways from ACR 2021 with Professor Tonia Vincent
- Explore video updates from EULAR 2020, including best practice for intra-articular injection
- Hear Professor Francis Berenbaum discuss recommendations from the 2019 ACR/AF guidelines
European League Against Rheumatism – EULAR 2021, expert roundtable
A roundtable discussion was formed comprising osteoarthritis (OA) experts to analyse important clinical OA updates from the European League Against Rheumatism (EULAR) 2021 Congress.
Meet the experts from the EULAR 2021 roundtable discussion, Professor Tonia Vincent, Professor Martin Englund and Dr Theresa Burkard.
The roundtable discussion focused on the assessment of OA-associated pain, 2021 guideline updates and knowledge gaps in OA-associated pain treatments.
Assessment of osteoarthritis-associated pain
Over 20% of chronic pain globally is associated with osteoarthritis (OA), with an increasing incidence associated with age and obesity. For many years, OA-associated pain was neglected, in part because of false beliefs on mechanisms and treatments. Currently, it is associated with important unmet needs, including suboptimal pain assessment.
In the videos below, the expert panel canvas key considerations in the best-practice assessment of OA-associated pain.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
ACR 2021 highlights
Follow an expert overview from Professor Tonia Vincent of ACR 2021 highlights, with commentary on emerging therapies, insights from epidemiology and genome-wide association studies, the role of growth factors and other targets, and the importance of multidisciplinary teams in osteoarthritis treatment today.
Meet the expert
Professor Tonia Vincent
Director, Centre for Osteoarthritis Pathogenesis,
University of Oxford, UK Professor Vincent studied medicine at University College London, qualifying in 1993. She trained as a junior doctor in London, later specialising in Rheumatology.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
European League Against Rheumatism – EULAR 2020
The EULAR e-scientific sessions took place in Frankfurt, broadcasting both live and recorded presentations. Sessions of particular interest to osteoarthritis (OA) are presented below.
Tramadol’s mortality risk could outweigh its benefits
According to a large population-based study in Canada, patients with OA treated with tramadol presented a 20–50% higher risk of death during the first year of treatment, compared with patients receiving NSAIDs.
Within a year of starting treatment with tramadol, there was a 20% increase in all-cause mortality when compared with naproxen (death rate of 21.5 vs 17.8 per 1,000 person-years, respectively; hazard ratio [HR] of 1.2). Similar results were observed when comparing tramadol with diclofenac (HR, 1.3) and cyclooxygenase (COX)-2 inhibitors (HR, 1.5). However, all-cause mortality was lower with tramadol than codeine (21.5 vs 25.5 per 1,000 person-years; HR, 0.8).
These findings add further weight to the excess mortality risk of tramadol highlighted last year by Zeng et al. in JAMA3 [link: dx.doi.org/10.1001/jama.2019.1347]
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Join Professor Francis Berenbaum to find out the key changes and recommendations from the 2020 ACR/AF guidelines
The recent update of the 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) guidelines for the comprehensive management of osteoarthritis (OA) of the Hand, Hip, and Knee contained a number of notable changes and recommendations7.
Below you can discover the key changes to the guidelines as well as important considerations in OA physical therapy. Also stay up to date on studies comparing physical therapy and glucocorticoids, the impact of non-steroidal anti-inflammatory drugs (NSAIDs) on coronavirus disease 2019 (COVID-19) susceptibility, anti-nerve growth factor (anti-NGF) efficacy and safety, and research into anti-interleukin-6 (anti-IL6) treatments.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
- Perrot S. Osteoarthritis Pain: Pathophysiology, Diagnosis, and Management. 2016. https://s3.amazonaws.com/rdcms-iasp/files/production/public/Content/ContentFolders/GlobalYearAgainstPain2/2016/FactSheets/English/13. Osteoarthritis Pain.pdf. Accessed 21 September 2021.
- Unruh AM. Pain in women. Pain Research and Management. 2008;13(3):199–200.
- Zeng C, Dubreuil M, Larochelle MR, Lu N, Wei J, Choi HK, et al. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA. 2019;321(10):969–982.
- Pelle T, Bevers K, Van Der Palen J, Van Den Hoogen FHJ, Van Den Ende CHM. Development and evaluation of a tailored e-self-management intervention (dr. Bart app) for knee and/or hip osteoarthritis: Study protocol. BMC Musculoskelet Disord. 2019;20(1):1–12.
- Pelle T, Bevers K, van der Palen J, van den Hoogen FHJ, van den Ende CHM. Effect of the dr. Bart application on healthcare use and clinical outcomes in people with osteoarthritis of the knee and/or hip in the Netherlands; a randomized controlled trial. Osteoarthr Cartil. 2020;28(4):418–427.
- Kedor C, Detert J, Rau R, Wassenberg S, Listing J, Klaus P, et al. Hydroxychlotoquine in patients with inflammatory and erosive osteoarthritis of the hands: Results of a randomized, double-blind, placebo controlled, multi-centre, investigator-initiated trial (OA TREAT). Ann Rheum Dis. 2020;79(Suppl 1):115 [0P0186].
- Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220–233.
- Deyle GD, Allen CS, Allison SC, Gill NW, Hando BR, Petersen EJ, et al. Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee. N Engl J Med. 2020;382(15):1420–1429.
- Chandan JS, Zemedikun DT, Thayakaran R, Byne N, Dhalla S, Acosta‐Mena D, et al. Non‐steroidal anti‐inflammatory drugs and susceptibility to COVID‐19. Arthritis Rheumatol. 2020;art.41593.
- Schnitzer T, Berenbaum F, Conaghan PG, Dworkin R, Yamabe T, Davignon I, et al. Clinically Important Improvement in Osteoarthritis Pain at Week 16 after Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies. In: Arthritis and Rheumatology. 2020: 3310–3311.
- Hunter D, Neogi T, Churchill M, Shirinsky I, Omata M, White A, et al. Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: results from a 56-Week Randomized NSAID-Controlled Study. Arthritis and rheumatology. 2020;72(SUPPL 10):3311‐3313.
- Neogi T, Hunter D, Churchill M, Shirinsky I, Omata M, White A, et al. Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: results from a 56-Week Randomized NSAID-Controlled Study. Arthritis and rheumatology. 2020;72(SUPPL 10):3314‐3316.
- NCT02477059, Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02477059. Accessed 8 January 2021.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors Pfizer and Lilly, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.